6-K ·Filed Sep 10, 2026

GSK

GSK plc
NEUTRAL
Impact 1/10
Horizonimmediate Processed22d 6h ago SEC0001654954-26-008255
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine plan-related PDMR transaction with no trading signal. No action warranted. Monitor next quarterly filing for operational updates.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+5d ⚠ clustered
GSK ▲ +6.11% at T+5d
NEUTRAL call ✓ call won +6.11% · α vs SPY +6.61% · entry $48.12 → $51.06
Next anchor: T+20d in 6d
Latest observation: T+15 +3.03% FF3 residual α
Entry anchored
Sep 10, 10:31 AM ET
via 1-min bar
T+1d
+0.02%
call +0.02% · α -0.83%
$48.13
settled 21d ago
T+5d
+6.11%
call +6.11% · α +6.61%
$51.06
settled 15d ago
T+20d
—
call — · α —
—
in 6d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

This is a routine 6-K filing disclosing a PDMR transaction: Maya Martinez-Davis, President US, acquired 9.837 notional ADS at $48.54 within her GSK Executive Supplemental Savings Plan account. The transaction is a plan-related notional acquisition, not an open-market purchase, and is immaterial in size (~$477 total). No material financial or operational information is disclosed.

Key Facts

  • Maya Martinez-Davis, President US, acquired 9.837 notional ADS at $48.54 on 2026-09-08 within her GSK Executive Supplemental Savings Plan account.
  • Total value of the transaction is approximately $477, which is immaterial relative to GSK's $98.4B market cap.
  • This is a plan-related notional acquisition, not a discretionary open-market purchase, and carries no signaling value.

Financial Impact

No material financial impact — transaction value ~$477, immaterial for a $98.4B market cap company.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-008255
Document: 0001654954-26-008255-index-headers.html0001654954-26-008255
Document: 0001654954-26-008255-index.html0001654954-26-008255
Document: 0001654954-26-008255.txt0001654954-26-008255
42 reports for GSK
Performance horizon
69% Hit rate 11 of 16 directional calls best @ T+60▲ +7.85%Jun 16, 2026
Filters
Rows
Reports for GSK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
6-K
NEUTRAL ★ 5/10
$50.01 $50.22▲ +0.42%▼ −0.40%$47.03 (−5.96%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.03 (−6.03%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.03 (−6.03%)
Sep 11, 2026
21d ago
6-K
NEUTRAL ★ 1/10
$48.13 $50.22▲ +4.34%▲ +4.56%$47.03 (−2.29%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 1/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.03 (−2.27%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 3/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.03 (−2.27%)
Sep 1, 2026
4w ago
6-K
NEUTRAL ★ 1/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.03 (−7.17%)
Sep 1, 2026
4w ago
6-K
BULLISH ★ 6/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.03 (−7.17%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 1/10
$51.43 $50.44▼ −1.92%▼ −1.80%$47.03 (−8.56%)
Aug 24, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$51.78 $50.25▼ −2.95%▼ −3.42%$47.03 (−9.17%)
Showing 10 of 42

US Market Status

Market Closed — Opens Mon (64h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access